Primary ITP
Typical setting: No associated disorder is identified after appropriate assessment.
Loss of immune tolerance produces platelet and megakaryocyte-directed antibodies and T-cell responses.
ITP module
Understand how antiplatelet immunity accelerates clearance and impairs production, causing isolated thrombocytopenia whose treatment follows bleeding risk rather than count alone.
Clinically reviewed by Mark · NMC-registered nurse
Aetiology
Different triggers converge on the condition's central pathological process.
Typical setting: No associated disorder is identified after appropriate assessment.
Loss of immune tolerance produces platelet and megakaryocyte-directed antibodies and T-cell responses.
Typical setting: HIV, hepatitis C, and other infections can be associated.
Molecular mimicry, immune activation, altered production, and splenic effects create thrombocytopenia.
Typical setting: SLE and antiphospholipid-associated disease may include immune platelet loss.
Systemic B- and T-cell dysregulation generates platelet-reactive immunity.
Typical setting: CLL and lymphoma disrupt normal immune regulation.
Abnormal B-cell clones or secondary autoimmunity increase platelet clearance.
Typical setting: Common variable immune deficiency and related disorders can paradoxically cause autoimmunity.
Dysregulated antibody responses target platelets despite impaired protective immunity.
Typical setting: Quinine, selected antibiotics, and other medicines trigger abrupt severe falls.
Drug-dependent antibodies bind platelet epitopes in the presence of the medicine; stopping exposure is essential.
Typical setting: A subset of patients improves after eradication in populations where the association is relevant.
Chronic antigenic stimulation and cross-reactive immunity may sustain platelet destruction.
Typical setting: An immune trigger precedes otherwise typical ITP.
Transient immune cross-reactivity often resolves more readily in children than chronic adult disease.
Mechanism chain
Follow each link and use it to predict the next clinical consequence.
B cells, T cells, and antibodies target platelet glycoproteins or related structures.
IgG and immune signals mark circulating platelets for recognition.
Keep exploring